| Earnings Per Share |
NOTE 34. EARNINGS PER SHARE
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Consolidated |
|
| |
June 30, 2026
A$ |
|
|
June 30, 2025
A$ |
|
|
June 30, 2024
A$ |
|
| Loss after income tax attributable to the owners of Immutep Limited |
|
|
(79,304,563 |
) |
|
|
(61,434,165 |
) |
|
|
(42,716,625 |
) |
|
|
|
|
| |
|
Number |
|
|
Number |
|
|
Number |
|
| Weighted average number of ordinary shares used in calculating basic earnings per share (EPS) |
|
|
1,471,576,261 |
|
|
|
1,455,818,442 |
|
|
|
1,201,061,930 |
|
| Weighted average number of ordinary shares used in calculating diluted earnings per share (EPS) |
|
|
1,471,576,261 |
|
|
|
1,455,818,442 |
|
|
|
1,201,061,930 |
|
|
|
|
|
| |
|
Cents |
|
|
Cents |
|
|
Cents |
|
| Basic earnings per share |
|
|
(5.39 |
) |
|
|
(4.22 |
) |
|
|
(3.56 |
) |
| Diluted earnings per share |
|
|
(5.39 |
) |
|
|
(4.22 |
) |
|
|
(3.56 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
| Information concerning other notes and options issued: The following table summarizes the convertible notes, performance rights, listed options and unlisted options that were not included in the calculation of weighted average number of ordinary shares because they are anti-dilutive for the periods presented.
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Consolidated |
|
| |
June 30, 2026
Number |
|
|
June 30, 2025
Number |
|
|
June 30, 2024
Number |
|
| Unlisted options* |
|
|
— |
|
|
|
847,600 |
|
|
|
847,600 |
|
| Convertible notes |
|
|
— |
|
|
|
7,432,958 |
|
|
|
7,261,072 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-executive director performance rights |
|
|
4,695,065 |
|
|
|
1,211,112 |
|
|
|
2,161,392 |
|
| Performance rights |
|
|
11,994,156 |
|
|
|
16,237,064 |
|
|
|
13,870,535 |
|
| * |
This is related to warrant associated with convertible notes, please refer to note 19 for more details. | On November 5, 2019, there was a 10 to 1 share consolidation. The consolidated comparative balance has therefore been adjusted accordingly.
|